Author: Customer Service

Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Announced Cincinnati Children’s Applied Gene and Cell Therapy Center (“AGCTC”) as Lead Manufacturing Partner Appointed Andrew Fang, Ph.D., as Head of Business Development BRISBANE, Calif., May 14, 2026 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update. “We made strong progress in the first quarter as we continued to execute across our lead program TPST-2003,” said Matt Angel, Ph.D., President and Chief Executive Officer of Tempest....

HOUSTON, May 14, 2026 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), an energy-systems platform company that enables the safe, certifiable deployment of ultra-high-power lithium battery systems for space and defense programs, mobility applications, hyperscale AI data centers, and telecom infrastructure OEMs, today announced its financial results for the first quarter 2026. First Quarter 2026 Financial Results: Revenues: Revenue increased 98% to $4,846,430 in the first quarter ended March 31, 2026, from $2,448,606 reported in the same year-ago period. Gross Margins: Gross margin was 29% in the first quarter ended March 31, 2026, compared to 8% in the same year-ago period. Selling, General and Administrative (SG&A) Expenses: SG&A expenses decreased...

FRE1 of $1.2 million and SRE1 of $2.0 million for the first quarter of 2026, resulting in Segment Income of $3.3 million1 representing a 41% increase, or $1.2 million, as compared to prior year. As compared to fourth quarter 2025, Segment Income increased by $2.9 million Strong quarter for Insurance Solutions with SRE of $2.0 million, up $2.0 million year-over-year, and $3.1 million as compared to fourth quarter 2025 Asset Management FRE declined to $1.2 million, but earnings quality improved significantly. FRE down $1.0 million year-over-year, and down $0.3 million as compared to fourth quarter 2025 During the first quarter, Mount Logan-managed Opportunistic Credit Interval Fund (SOFIX) entered an agreement to acquire $100+ million of assets for Yieldstreet Alternative Income Fund. Currently estimated to close during the third quarter...

Q1 2026 Production Exceeds Expectations on Strong Initial Well Performance Adjusted EBITDA Increased 404% from Q1 2025(1) HOUSTON, May 14, 2026 (GLOBE NEWSWIRE) — PEDEVCO Corp. (NYSE American: PED) (“PEDEVCO” or the “Company”), a publicly traded energy company engaged in the acquisition and development of strategic oil and gas assets in the Rocky Mountain region, today reported unaudited financial results for the first quarter ended March 31, 2026. Financial & Operational Highlights($000s except as noted) Q1 2026 Q1 2025 Q4 2025 Change YoY Change QoQAverage Daily Production (Boe/d) 8,091 1,707 5,310 +374% +52%Revenue $40,222 $8,736 $23,082 +360% +74%Net (Loss) Income $(25,627) $140 $(8,501) NM(2) NM(2)Adjusted EBITDA(2) $21,513 $4,269 $15,392 +404% +40%(1) Adjusted EBITDA is a non-GAAP financial measure....

Strategic Progress Accelerated with Transformational Acquisition and Launch of The NEW Data I/O, Including New Programming-as-a-Service Revenue Model  Second Quarter Revenue Guidance for Approximately 20% Sequential Growth from First Quarter REDMOND, Wash., May 14, 2026 (GLOBE NEWSWIRE) — Data I/O Corporation (NASDAQ: DAIO), the leading global provider of data programming and security provisioning solutions for microcontrollers, security ICs and memory devices, today announced financial results for the first quarter ended March 31, 2026. First Quarter 2026 and Recent HighlightsTransformational acquisition announced $9 million direct investment strengthens balance sheet Bookings of $4.2 million increase sequentially and from prior year period Operating expenses excluding 1x items decline sequentially and from prior year period Operating...

First Tracks launched April 20th with a two-year cash-runway to advance ANB033 through celiac disease and eosinophilic esophagitis Phase 1b data and plans to initiate Phase 2 trials across four indicationsSAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) — First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update. “First Tracks Bio launched to advance a focused, high-value immunology portfolio that can create meaningful impact and a future where autoimmune diseases no longer define a patient’s life,” said Daniel Faga, president and chief executive officer. “We remain committed to executing...

Presented new data on CLD-401 at the AACR conference in San Diego, CA, detailing the profound immune changes in the tumor microenvironment induced by CLD-401; IND filing for CLD-401 expected by end of 2026 Presented new data on RedTail at the AACR conference in San Diego, CA detailing the use of the RedTail platform to create in vivo T-cell engagers that simultaneously express both a T-cell engager and a T-cell activator at high levels exclusively in the tumor microenvironment; presented new data on CLD-501, a TROP-2 in vivo T-cell engager Demonstrated $1 million reduction in general and administrative expenses from Q1-2025 to Q1-2026 Speaker presentation at ASGCT conference in Boston, MA highlighting IL15-SA expression may dramatically expand the therapeutic window of IL-15-mediated treatment Speaker presentation at IOVC conference showcasing...

Revenue Grows 8% Year-Over-Year to $4.1 Million; Import and Metal Verticals Deliver Strong Double-Digit Growth NORTH WALES, PA, May 14, 2026 (GLOBE NEWSWIRE) — Toppoint Holdings Inc. (NYSE American: TOPP), a truckload services and solutions provider focused on the recycling export supply chain, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Highlights •  Revenue of $4.1 million, an increase of 8% compared to $3.8 million in Q1 2025 •  Import revenue surged 61.8% year-over-year to $1.4 million •  Metal vertical revenue grew 164.8% year-over-year to $565,647 •  Net cash used in operating activities improved by approximately $93,650 versus the prior-year quarter •  Total assets of $10.3 million as of March 31, 2026 •  Expanded geographic footprint into Houston, TX, and continued growth...

Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial  Company to provide detailed data update from Phase 2 CRDF-004 trial in rapid oral presentation at American Society of Clinical Oncology Annual Meeting Leadership additions position Company to execute on key upcoming clinical and regulatory milestones SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced financial results for the first quarter ended March 31, 2026, and provided a business update. “This quarter was marked by the positive data update from our randomized Phase 2 CRDF-004 trial of onvansertib in first-line RAS-mutated metastatic...

ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million Fortress’ consolidated net income attributable to common stockholders for the first quarter of 2026 was $108.4 million, or $3.44 per common share (basic) and $2.82 per common share (diluted) MIAMI, May 14, 2026 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2026. Lindsay A. Rosenwald, M.D., Fortress’ Chairman,...